Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TNG456

Small molecule · Inhibitor of protein arginine methyltransferase 5 (PRMT5) (PRMT5) · developed by Tango Therapeutics

Phase 1/2 Most advanced trial
TNGX Developer
1 Registered trials

What is TNG456?

TNG456 is an orally bioavailable, blood-brain-barrier penetrant small molecule that selectively inhibits PRMT5 bound to methylthioadenosine (MTA), acting specifically in MTAP-deleted cancer cells. By reducing methylation of arginine residues on histone and non-histone proteins, it alters gene expression that governs cell proliferation. It is studied in non-small cell lung cancer, glioblastoma and other solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
protein arginine methyltransferase 5 (PRMT5) (PRMT5)
Mechanism
Inhibitor of protein arginine methyltransferase 5 (PRMT5) (PRMT5)
Pathways
arginine methylation of histone and non-histone proteins, gene expression regulation
Therapy area
Oncology
Developer
Tango Therapeutics, Inc. (TNGX)
Also in trials of
LLY
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06810544 Phase 1/2 Non Small Cell Lung Cancer Recruiting TNGX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Brain TumorGlioma Glioblastoma MultiformeGlioma, MalignantLung CancerNon Small Cell Lung CancerNon-Small Cell AdenocarcinomaSolid Tumor

Other drugs acting on PRMT5

More from Tango Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TNGX page.

Follow TNGX, the company behind TNG456

See TNGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TNGX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.